To date, we have had a total of 38 patent applications, and 3 patents were issued in the past 3 months. All thanks to our dedicated team of researchers.
-Patent No. 11,235,058, Immunotherapeutic constructs and methods of their use, February 1, 2022
Development of antioxidant nanoparticle platform for delivery of siRNA and chemodrugs, Department of Chemistry Seminar Series, Portland State University, May 18th, 2018
Development of a Targeted Therapeutic and Radiation Sensitizer for Lung Cancer, 63rd annual Radiation Research Society (RRS) meeting, Cancun, MX, October 15th, 2017
siRNA-nanoparticles for treating drug-resistant breast cancer, Gordon RNA Technology, Ventura, CA, Feb 1-6. 2015
New methodologies for cancer target identification, personalized medicine in cancer care, and novel therapies based on nanomedicine, BDMS Meeting, Bangkok, Thailand, December 26, 2014 (invited).
OHSU’s effort to understand complex biological systems of cancer leading to targeted therapy with siRNA-nanoparticles, Siriraj School of Medicine, Bangkok, Thailand, December 22, 2014 (invited).
Bioreducible-crosslinked polymer coated mesoporous silica nanoparticles for siRNA targeted delivery to HER2+ breast cancer, 4th International Conference on Nanotek & Expo, San Francisco, CA, December 12, 2014 (invited).
Antibody-conjugated Nanoparticle Platform for Targeted Delivery of SiRNA to HER2+ Breast Cancer, BMES Annual Meeting 2014, San Antonio, TX, October 24, 2014.
SiRNA-mediated Targeting of HER2 as a Viable Approach for Treating Trastuzumab Resistant Breast Cancer, WIN Symposium 2014, Paris, France, June 23, 2014.
Development of a nanoparticle platform for the targeted delivery of siRNA to HER2-positive breast cancers, AACR Annual meeting 2014, San Diego, CA, April 9, 2014.
Nanoparticle Platform for siRNA Delivery with ROS Scavenging Properties for Treating Fibrosis, Keystone Symposium, Fibrosis: From Bench to Bedside (C4), Keystone, CO, March 24, 2014.
Development of a Nanoparticle platform for the Targeted Delivery of siRNA to HER2-positive Breast Cancers, 53rd Annual Meeting and ToxExpo, Society of Toxicology, Phoenix, AZ , March 25, 2014.
Novel Oral Detoxification of Mercury, Cadmium, and Lead with Thiol-Modified Mesoporous Silica, 53rd Annual Meeting and ToxExpo, Society of Toxicology, Phoenix, AZ, March 27, 2014.
Potential Use of Mesoporous Silica Nanoparticle for siRNA Delivery Agent and ROS Scavenger in Fibrotic Diseases, IEEE-Nanomed 2013, Phuket, Thailand, November 11, 2013.
Development of Lanthanide-loaded Mesoporous Silica Nanoparticles for Multi-parametric Single Cell Analysis by Mass Cytometry, IEEE-Nanomed 2013, Phuket, Thailand, November 12, 2013.
Nanoparticle platform for targeted delivery of siRNA and chemotherapies, (keynote presentation), IEEE-Nanomed 2013, Phuket, Thailand, November 12, 2013.
Nanoparticle platform for therapeutic siRNA delivery to HER2 positive breast cancer, TechConnect World 2012 – Nanotech, Santa Clara, CA, June, 2012.